Overview

Gastric Cancer 70 Gene Testing integrates targeted-therapy genes, chemotherapy-related genes, and mismatch repair markers to define the molecular subgroups most likely to benefit from a specific treatment path. Gastric cancer is biologically heterogeneous, so a one-size-fits-all approach leaves many patients on suboptimal regimens. By sorting cases into biomarker-defined populations, the panel helps clinicians direct the right patient to the right option rather than treating the diagnosis alone.

Identifying MSI-High and Mismatch Repair Deficient Cases

The panel assesses microsatellite instability and mismatch repair status, which mark tumors with defective DNA repair. These cases represent a distinct population with a different therapeutic outlook, including eligibility for checkpoint inhibitor strategies under validated tissue-agnostic claims. Separating mismatch repair deficient from proficient tumors is therefore a core population-defining step that changes the subsequent treatment logic for the individual patient.

Targeting HER2 and Other Actionable Drivers

Beyond repair markers, the assay covers genes whose alterations correspond to targeted agents used in gastric cancer management, such as HER2 amplification. Confirming these alterations identifies the subgroup that may benefit from anti-HER2 therapy, while their absence steers the plan toward alternative routes. Reporting the alteration with its validated association lets the team match the patient to the corresponding population rather than inferring it from histology alone.

Chemotherapy Context for the Selected Population

The chemotherapy gene track adds pharmacogenomic context so that, within the chosen population, cytotoxic selection can be tempered by the patient's likely handling of specific agents. This is especially useful when the biomarker-defined subgroup still requires chemotherapy as part of the plan. The panel thus supports both the selection of the population and the refinement of therapy within it.

From Subgroup to Treatment Path

Defining the population is only the first step; the panel should also indicate the corresponding treatment path for each subgroup it identifies. For mismatch repair deficient cases that means noting immune checkpoint eligibility, while HER2-positive cases point toward anti-HER2 therapy. Linking each subgroup to its established route in the report lets the multidisciplinary team move directly from molecular classification to a concrete plan.

Fitting the Result Into Care

Defining a population is only the first step; the result must reach the right decision point. Reports should make the population assignment explicit, naming the marker that drives it and the corresponding treatment path, so the recommendation survives handoff between pathology, oncology, and surgery. A clear population label also helps audit why a given patient received a particular regimen, which matters for both quality review and reimbursement documentation.

FAQ

Q: Which population does microsatellite instability status define? A: It identifies mismatch repair deficient tumors, a subgroup with distinct biology and potential eligibility for immune checkpoint strategies.

Q: Does the panel only help targeted therapy selection? A: No, it also provides chemotherapy-related context and repair markers that together define the appropriate patient population.

Q: Why is population selection important in gastric cancer? A: Gastric tumors vary widely at the molecular level, so biomarker-defined subgroups respond differently to the same treatment.